Burney Co. Buys 3,457 Shares of Merck & Co., Inc. (MRK)

Burney Co. lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 11.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,188 shares of the company’s stock after buying an additional 3,457 shares during the quarter. Burney Co.’s holdings in Merck & Co., Inc. were worth $2,015,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Rockland Trust Co. bought a new stake in Merck & Co., Inc. during the 2nd quarter valued at approximately $3,949,000. Sawyer & Company Inc raised its stake in Merck & Co., Inc. by 10.7% during the 2nd quarter. Sawyer & Company Inc now owns 22,984 shares of the company’s stock valued at $1,395,000 after purchasing an additional 2,215 shares during the period. Steward Partners Investment Advisory LLC raised its stake in Merck & Co., Inc. by 37.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 122,748 shares of the company’s stock valued at $7,451,000 after purchasing an additional 33,153 shares during the period. Bogart Wealth LLC bought a new stake in Merck & Co., Inc. during the 2nd quarter valued at approximately $2,084,000. Finally, HL Financial Services LLC raised its stake in Merck & Co., Inc. by 0.7% during the 2nd quarter. HL Financial Services LLC now owns 217,281 shares of the company’s stock valued at $13,189,000 after purchasing an additional 1,540 shares during the period. 72.18% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently issued reports on the company. Credit Suisse Group lifted their target price on Merck & Co., Inc. from $71.00 to $81.00 and gave the company an “outperform” rating in a research note on Thursday. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research note on Monday, October 8th. Bank of America lifted their target price on Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Guggenheim assumed coverage on Merck & Co., Inc. in a research note on Monday, October 8th. They set a “buy” rating on the stock. Finally, BMO Capital Markets reissued a “buy” rating and set a $70.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, July 22nd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Merck & Co., Inc. has an average rating of “Buy” and a consensus target price of $69.61.

NYSE MRK opened at $69.81 on Friday. The company has a market cap of $191.27 billion, a price-to-earnings ratio of 17.54, a PEG ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. Merck & Co., Inc. has a 1-year low of $52.83 and a 1-year high of $72.89.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.03. The business had revenue of $10.47 billion during the quarter, compared to analysts’ expectations of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.01 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 4.27 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, October 5th. Shareholders of record on Monday, September 17th were issued a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 2.75%. The ex-dividend date was Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio is presently 48.24%.

In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 279,850 shares of the firm’s stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $72.07, for a total transaction of $20,168,789.50. Following the completion of the transaction, the chairman now owns 971,800 shares in the company, valued at approximately $70,037,626. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Kenneth C. Frazier sold 228,091 shares of the firm’s stock in a transaction that occurred on Tuesday, July 31st. The shares were sold at an average price of $65.00, for a total value of $14,825,915.00. Following the transaction, the chairman now owns 938,788 shares of the company’s stock, valued at approximately $61,021,220. The disclosure for this sale can be found here. Insiders have sold a total of 929,360 shares of company stock valued at $64,370,599 in the last 90 days. 0.32% of the stock is currently owned by company insiders.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: Understanding the different types of bonds

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply